Central Nervous System Lymphoma
📧 Sign up to get email alerts when something new happens for Central Nervous System Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Real World Data on Ibrutinib Use in PCNSL Rel/Ref
Real-world data study update on the use of ibrutinib in relapsed or refractory primary central nervous system lymphoma.
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy [Phase 2]
This Phase 2 clinical trial assessed nivolumab as maintenance therapy in newly diagnosed primary central nervous system lymphoma with persis…
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) [Phase 2]
Phase 2 clinical trial TEDDI-R evaluating a combination of temozolomide, etoposide, liposomal doxorubicin (Doxil), dexamethasone, ibrutinib,…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma [Phase 2]
Phase 2 trial evaluating Anbalcabtagene Autoleucel for relapsed/refractory primary central nervous system lymphoma and diffuse large B-cell …
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
A recruiting clinical study examining metabolic and immunomic differences in primary central nervous system lymphoma and diffuse large B-cel…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Long-term Follow-up Study of Patients Receiving CAR-T Cells
This clinical trial update outlines a long-term follow-up study of patients who received CAR-T cell therapy. Sponsored by the Medical Colleg…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma [NA]
This clinical trial update describes a forthcoming study evaluating a combination regimen of Relmacabtagene autoleucel CAR-T cells, autologo…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) [Phase 1, Phase 2]
A clinical trial update for GNC-038, a tetra-specific antibody, in primary central nervous system lymphoma and relapsed or refractory second…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA） [NA]
Clinical trial evaluating the efficacy and safety of combining methotrexate or thiotepa or temozolomide with orelabrutinib and selinexor in …
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL [Phase 2, Phase 3]
This document reports a planned Phase 2/3 clinical trial evaluating Orelabrutinib combined with teniposide, rituximab, and methotrexate for …
-
CLINICAL_TRIALS research · 2025-09-16Clinical Trial Update: Selinexor in Combination With MTX+Ritu to Treat R/R CNSL [Phase 1, Phase 2]
A Phase 1/2 clinical trial (NCT05698147) is evaluating selinexor in combination with methotrexate and rituximab for relapsed/refractory cent…
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma [Phase 1]
Phase 1 trial update on cord blood-derived CAR-NK cells targeting CD19 for refractory/recurrent central nervous system lymphoma; the study i…
-
CLINICAL_TRIALS research · 2025-08-13Clinical Trial Update: Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL [Phase 2]
This entry notes a Phase 2 clinical trial at the University of Cologne evaluating the combination of methotrexate, tafasitamab, lenalidomide…
-
CLINICAL_TRIALS research · 2025-08-06Clinical Trial Update: Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). [Phase 1, Phase 2]
This Clinical Trial Update describes a fourth-generation CD19/CD22 dual-targeting CAR T-cell therapy being evaluated in Phase 1/2 for highly…
-
CLINICAL_TRIALS research · 2025-07-31Clinical Trial Update: A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the combination of selinexor, temozolomide, and an anti-PD-1 antibody for relapsed/refractory primary …
-
CLINICAL_TRIALS research · 2025-07-30Clinical Trial Update: Axi-cel in CNS Lymphoma [Phase 1]
Phase 1 study of axicabtagene ciloleucel in CNS lymphoma is active but not recruiting, with Dana-Farber as sponsor.
-
CLINICAL_TRIALS research · 2025-07-20Clinical Trial Update: Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL [NA]
This clinical trial is evaluating a combination of teniposide, a PD-1 monoclonal antibody, and selinixor for relapsed or refractory primary …
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma [Phase 1]
Phase 1 clinical trial investigating intracerebroventricular administration of autologous CD19 CAR T cells for central nervous system lympho…
-
CLINICAL_TRIALS research · 2025-06-26Clinical Trial Update: Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL [Phase 2]
Phase 2 clinical trial of Paxalisib (GDC-0084) for recurrent or refractory primary central nervous system lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study
The CLIMB study, conducted by Royal Marsden NHS Foundation Trust, investigates imaging and molecular biomarkers for central nervous system l…
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma [Phase 2]
Phase 2 clinical trial evaluating high-dose chemotherapy with gemcitabine, busulfan, and thiotepa followed by autologous stem cell transplan…
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma.
This clinical trial update indicates ongoing recruitment for a study aiming to improve safety and accuracy of stereotactic brain biopsies in…
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: The Role of Surgical Resection AND Stereotactic Radiosurgery in Primary Central Nervous System -Diffuse Large B Cell Lymphoma
This completed clinical trial investigates the potential role of surgical resection and stereotactic radiosurgery in treating primary centra…
-
CLINICAL_TRIALS research · 2025-06-05Clinical Trial Update: Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response [Phase 2]
Phase 2 trial evaluating maintenance obinutuzumab in patients with primary central nervous system lymphoma who have achieved a complete or p…
-
CLINICAL_TRIALS research · 2025-06-04Clinical Trial Update: A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas [Phase 2]
Phase 2 pilot study evaluating acalabrutinib in relapsed or refractory central nervous system lymphomas; the trial is currently active but n…